NextTrip Inc (OQ:NTRP)
Business Focus: Travel Agents
Apr 02, 2024 09:01 am ET
NextTrip Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
SUNRISE, FL / ACCESSWIRE / April 2, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip", "we," "our," or the "Company"), a travel technology company, has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communications program across all key markets.
Feb 04, 2021 08:00 am ET
Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) announced today that it has received its first batch of synthetic Bryostatin. The Company has an exclusive licensing agreement with Stanford University ("Stanford") for synthetic Bryostatin for all neurologic indications, as well as a supply agreement in place with Bryologyx, Inc. as previously announced. To date, Synaptogenix has relied upon supply of Bryostatin, derived from natural sources, from the National Cancer Institute of Health.
Dec 02, 2020 08:00 am ET
Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals
NEW YORK and MANALAPAN TOWNSHIP, N.J., Dec. 2, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovative therapeutics for men's health conditions ("Metuchen"), today announced the completion of their previously announced merger following the satisfaction of all closing conditions required by the amended merger agreement (the "Merger Agreement"). Neurotrope shareholders also approved the spin-off of substantially all of Neurotrope's existing assets, operations and liabilities, except for certain
Nov 20, 2020 08:00 am ET
Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) ("Neurotrope" or the "Company") announced today that its Board of Directors has approved the conditional distribution and set the shareholder of record and distribution dates in connection with the previously announced spin-off (the "Spin-Off") of its wholly-owned subsidiary, Neurotrope Bioscience, Inc. ("NBI"). Subject to the closing of Neurotrope's proposed merger with Metuchen Pharmaceuticals, LLC ("Metuchen"), shareholders and certain warrant holders of record of Neurotrope on November 30, 2020 (the "Record Date") wi
Jul 30, 2020 09:00 am ET
Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1, Partially Funded by NIH, for Alzheimer's Disease
NEW YORK, July 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced that its wholly-owned subsidiary, Neurotrope Bioscience, Inc. ("NBI"), has entered into a services agreement with Worldwide Clinical Trials ("WCT") to support site recruitment and activation for the Company's ongoing Phase 2 study of bryostatin-1 in the treatment of moderately severe Alzheimer's disease ("AD"). The Phase 2 clinical study is being conducted in collaboration with the National Institutes of Health ("NIH") under a $2.7 million grant to Neurotrope. Details of t
Jun 10, 2020 08:41 am ET
Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia
NEW YORK, June 10, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced its entry into a strategic agreement with BryoLogyx Inc., www.BryoLogyx.com, for the supply of synthetic, GMP-certified Bryostatin-1, manufactured by Albany Molecular Research, Inc. ("AMRI"), a leading global CDMO provider of advanced drug development and manufacturing solutions. Neurotrope expects to use the synthetic Bryostatin-1 in its clinical development initiatives aimed at advancing its lead product candidate for the treatment of Alzheimer's disease ("AD") and othe
May 28, 2020 09:00 am ET
Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease
NEW YORK, May 28, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The Phase 2 clinical study will be conducted in collaboration with the National Institutes of Health (NIH) under a $2.7 million grant to Neurotrope. After reviewing the data from the previous trial with Key Opinion Leaders and the NIH, we designed a study to evaluate the long-term therapeutic effect of Bryostatin-1 in the absence of Namenda® (memantine) in patients with AD. The Company has en
May 26, 2020 04:20 pm ET
Neurotrope Announces Investor Update Conference Call
NEW YORK, May 26, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, L.L.C. to form Petros Pharmaceuticals, Inc. The investor call is scheduled for Thursday, May 28, 2020 at 11:00 AM ET.
May 18, 2020 08:45 am ET
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company
NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health conditions, today announced that the two companies have entered into a definitive merger agreement under which Metuchen and Neurotrope, Inc. ("Neurotrope") will merge in an all-stock transaction resulting in a newly formed holding company to be renamed Petros Pharmaceuticals, Inc. ("Petros").
Feb 03, 2020 05:15 pm ET
XpresSpa Appoints Robert Weinstein to Board of Directors
XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, announced that effective today, Mr. Robert Weinstein has been appointed to the Company’s Board of Directors (the “Board”) and also named Chairman of...
Oct 08, 2019 08:30 am ET
Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value
NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its plans to explore strategic alternatives to maximize shareholder value.
Sep 09, 2019 08:30 am ET
Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease
NEW YORK, Sept. 9, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that its confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD did not achieve statistical significance on the primary endpoint, which was change from baseline to Week 13 in the Severe Impairment Battery (SIB) total score.
Aug 13, 2019 08:30 am ET
Neurotrope Announces Publication Highlighting the Potential of Bryostatin as a Unique Neurorestorative Therapy
NEW YORK, Aug. 13, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that an article highlighting the synaptic deficiency hypothesis was published online in Trends in Pharmacological Sciences. This article presents an overview of the previous nonpharmacological interventions and pharmacological agents, including Bryostatin, that target synaptic functions in order to improve cognitive functions against AD-related memory impairment. T
Aug 05, 2019 08:30 am ET
Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results
NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today provided an update on clinical and corporate developments, including its ongoing confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD, and announced financial results for the second quarter ended June 30, 2019.
Jul 17, 2019 08:30 am ET
Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team
NEW YORK, July 17, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that two of the Company's Scientific Advisory Board members will be participating in a key opinion leader (KOL) call being sponsored by Oppenheimer & Co. Inc.'s Biotechnology team.
Jul 15, 2019 08:30 am ET
Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease
NEW YORK, July 15, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that the Company has concluded data collection in its confirmatory Phase 2 double blind, placebo controlled clinical trial of Bryostatin-1 in the treatment of moderately severe to severe AD.
Jul 11, 2019 08:30 am ET
Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmator
NEW YORK, July 11, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical- stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer's disease ("AD") is announcing that Dr. Daniel L. Alkon, the Company's President and CSO, will be honored among the recipients of the Cure Coin Award, at the InvestAcure Cure Coin Awards Reception on July 15, 2019 during the Alzheimer's Association International Conference in Los Angeles.
Apr 19, 2019 05:15 pm ET
Neurotrope Announces Inducement Grant to Newly-Appointed Chief Operating Officer and General Counsel
NEW YORK, April 19, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer's disease ("AD"), today announced the authorization of an inducement grant to newly-appointed Chief Operating Officer and General Counsel, Michael Ciraolo, J.D., Ph.D.
Apr 19, 2019 08:15 am ET
New Research: Key Drivers of Growth for Seritage Growth Properties, TrovaGene, VistaGen Therapeutics, Tecogen, Neurotrope, and Stellar Biotechnologies — Factors of Influence, Major Initiatives and Sus
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Seritage Growth Properties (NYSE:SRG), TrovaGene, Inc. (NASDAQ:TROV),...
Apr 01, 2019 08:30 am ET
Neurotrope Appoints Dr. Michael Ciraolo As General Counsel And Chief Operating Officer
NEW YORK, April 1, 2019 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease ("AD"), announced today that Michael Ciraolo, J.D., Ph.D., is joining the Company as general counsel and chief operating officer.
Mar 21, 2019 09:55 am ET
Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzheimer's Disease
NEW YORK, March 21, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today issued a statement on Biogen Inc.'s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer's disease.
Mar 13, 2019 08:30 am ET
Neurotrope Completes Enrollment Of Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease
NEW YORK, March 13, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that it has initiated dosing in the final patient in the Company's randomized, double-blind, placebo-controlled, confirmatory Phase 2 clinical trial of Bryostatin-1 in moderate to severe AD patients not on memantine. A total of 108 patients were enrolled into the study.
Mar 11, 2019 08:30 am ET
Neurotrope Reports Year End 2018 Financial Results
NEW YORK, March 11, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease ("AD"), provided financial results for the year ended December 31, 2018.
Feb 08, 2019 07:30 am ET
Neurotrope to Participate in the BIO CEO & Investor Conference
NEW YORK, Feb. 8, 2019 /PRNewswire/ -- Neurotrope Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Charles Ryan, J.D., Ph.D., Neurotrope's Chief Executive Officer, will be participating in an educational panel entitled, "Attacking Biological Mechanisms of Aging to Extend Healthspan" at the BIO CEO & Investor Conference in New York on Monday, February 11th, 2019 at 3:30 p.m. Eastern Time.
Feb 04, 2019 07:30 am ET
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute
NEW YORK, Feb. 4, 2019 /PRNewswire/ -- Neurotrope Inc. (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the research and clinical development of Bryostatin-1. Under the CRADA, Neurotrope will collaborate with the NCI's Center for Cancer Research, Pediatric Oncology Branch (POB) to develop a Phase I clinical trial testing the safety and toxicit
Jan 03, 2019 07:30 am ET
Neurotrope to Participate in the Sachs Associates 2nd Annual Neuroscience Innovation Forum
NEW YORK, Jan. 3, 2019 /PRNewswire/ -- Neurotrope Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Daniel Alkon, M.D., Neurotrope's President and Chief Scientific Officer, will be participating in a panel discussion entitled "Progress in Alzheimer's" at the Sachs Associates 2nd Annual Neuroscience Innovation Forum in San Francisco on Sunday, January 6th, 2019 at 10:25 a.m. Pacific Time.
Dec 17, 2018 08:02 am ET
Neurotrope Announces the Appointment of Two New Board Members
NEW YORK, Dec. 17, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced the appointment of two new members to its Board of Directors - Ivan Gergel, M.D., Managing Partner and Chief Medical Officer of New Rhein Healthcare Investors LLC, and Jonathan Schechter, Director of Investment Banking at Chardan Capital Markets.
Dec 17, 2018 08:01 am ET
Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease
NEW YORK, Dec. 17, 2018 /PRNewswire/ -- Neurotrope Inc. (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that data from its Phase 2, multidose, exploratory trial evaluating Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease were published online in the Journal of Alzheimer's Disease. The double-blind, placebo-controlled, Phase 2 trial, which was completed in May 2017, randomized patients 1:1:1 into 20 μg Bryostatin-1, 40 μg Bryostati
Dec 17, 2018 08:00 am ET
Neurotrope Announces $22.5 Million Registered Direct Offering
NEW YORK, Dec. 17, 2018 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq:NTRP) today announced the pricing of a registered direct offering of 5,012,677 shares of common stock and warrants to purchase up to an aggregate of 5,012,677 shares of common stock to institutional and other accredited investors. Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined purchase price of $4.495, resulting in gross proceeds of approximately $22.5 million. The warrants will be exercisable at a price of $4.37 per share beginning six months following the
Nov 19, 2018 09:00 am ET
Report: Developing Opportunities within Command Center, Neurotrope, Selecta Biosciences, InVivo Therapeutics, SeaSpine, and Senestech — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Command Center Inc. (NASDAQ:CCNI), Neurotrope, Inc. (NASDAQ:NTRP),...
Oct 24, 2018 08:30 am ET
Neurotrope Presents Updated Phase 2 Data of Bryostatin-1 in Moderate to Severe Alzheimer's Disease at the 11th Edition of CTAD
NEW YORK, Oct. 24, 2018 /PRNewswire/ -- Neurotrope Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced the presentation of updated data from the Phase 2, multidose, exploratory trial evaluating Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease ("AD"). The data were presented in a poster, entitled "Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer's Disease: Consistency of Multiple Evaluation Analyses" at th
Sep 27, 2018 08:30 am ET
Neurotrope to Present at the Ladenburg Thalmann 2018 Healthcare Conference
NEW YORK, Sept. 27, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced that Dr. Charles Ryan, Neurotrope's Chief Executive Officer, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference in New York on Tuesday, October 2nd, 2018 at 9:30 a.m. Eastern Time.
Sep 26, 2018 08:30 am ET
Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer's Disease (CTAD2018)
NEW YORK, Sept. 26, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced that updated data on its lead compound, bryostatin, will be presented during the 11th Edition of Clinical Trials on Alzheimer's Disease to be held in Barcelona, Spain from October 24th - 27th, 2018.
Sep 05, 2018 08:30 am ET
Neurotrope Enters into Collaboration with the Nemours / Alfred I. duPont Hospital for Children to Initiate a Clinical Trial in Fragile X Syndrome
NEW YORK, Sept. 5, 2018 /PRNewswire/ -- Neurotrope Inc. (NASDAQ: NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease (AD), is announcing a collaboration with The Nemours / Alfred I. duPont Hospital for Children ("Nemours") to initiate a clinical trial in children with Fragile X Syndrome ("Fragile X"). The planned protocol for the pilot open-label trial will dose Fragile X patients from 8 to less than 18 years of age, using a dosing regimen similar to that being tested in AD patients
Aug 28, 2018 08:30 am ET
Neurotrope Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018
NEW YORK, Aug. 28, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.
Aug 13, 2018 08:30 am ET
Neurotrope Provides Business Update and Reports Second Quarter 2018 Financial Results
NEW YORK, Aug. 13, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today provided a business update outlining recent clinical development progress and other noteworthy events that occurred subsequent to the end of the quarter and unaudited financial results for the quarter ended June 30, 2018.
Jul 25, 2018 08:30 am ET
At AAIC 2018, Neurotrope Presents Additional Clinical Results Showing Cognitive Improvement in Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients
NEW YORK, July 25, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) today presented additional clinical results from its recently completed Phase 2 trial demonstrating that moderate-to-severe Alzheimer's disease (AD) patients treated with 20 µg Bryostatin-1 showed evidence of sustained improvement in cognition compared with placebo in patients not on concomitant memantine treatment, with a safety profile similar to placebo. The data and comprehensive statistical analysis are being presented in the Developing Topics Poster Presentation, "Significant Cognitive Improvement with Bryostatin f
Jul 16, 2018 08:30 am ET
Neurotrope Announces the Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimer's Disease
NEW YORK, July 16, 2018 /PRNewswire/ -- Neurotrope Inc. (NASDAQ: NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing that the first patient has been enrolled into its confirmatory Phase 2 clinical trial with its lead Alzheimer's disease drug, Bryostatin-1. Patient recruitment will take place at approximately 30 clinical sites in the United States. This follow-on confirmatory clinical trial is planned to include 100 patients with moderate to severe AD (defined as a Mini Mental State Exam
Jul 11, 2018 08:30 am ET
Neurotrope Appoints Leading Experts in Alzheimer's Disease to its Scientific Advisory Board (SAB)
NEW YORK, July 11, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing that it has established its Scientific Advisory Board (SAB) comprised of experts in the fields of AD and other Neurological diseases.
Jul 02, 2018 08:30 am ET
Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting
NEW YORK, July 2, 2018 /PRNewswire/ -- Neurotrope Inc. (NASDAQ: NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing the acceptance of a presentation at the Alzheimer's Association International Conference 2018 (AAIC) being held in Chicago, from July 22-26, 2018.
May 07, 2018 08:30 am ET
Neurotrope, In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimer's Patients
NEW YORK, May 7, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), is announcing that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary (the "Company"), has completed the study design for its confirmatory Phase 2 clinical trial in moderate to severe Alzheimer's disease. The study was designed in consultation with a team of experts in the AD field who are highlighted below.
Feb 28, 2018 07:30 am ET
Neurotrope to Present at the Cowen and Company 38th Annual Health Care Conference
NEW YORK, Feb. 28, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Daniel Alkon, MD, President and Chief Scientific Officer of Neurotrope, will present at the Cowen and Company 38th Annual Health Care Conference to be held at the Boston Marriott Copley Place, from March 12th - 14th, 2018. The Corporate presentation is scheduled for Monday, March 12th at 4:50 PM.
Feb 07, 2018 07:30 am ET
Neurotrope to Present at BIO CEO & Investor Conference
NEW YORK, Feb. 7, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Daniel Alkon, MD, President and Chief Scientific Officer of Neurotrope, will present at the BIO CEO & Investor Conference to be held in New York City from February 12th-13th, 2018.
Jan 25, 2018 07:30 am ET
Neurotrope to Present at NobleCon 14th Annual Institutional Investor Conference
NEW YORK, Jan. 25, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Dr. Daniel Alkon, President and CSO, will provide a corporate overview at the NobleCon 14th Annual Institutional Investor Conference to be held at the W Hotel in Fort Lauderdale, FL from January 29th – 30th, 2018.
Jan 05, 2018 08:28 am ET
Neurotrope's Bryostatin Improves Cognition in Patients with Advanced Alzheimer's Disease Based on Further Analysis of Phase 2 Clinical Trial Data
NEW YORK, Jan. 5, 2018 /PRNewswire/ -- Neurotrope (NASDAQ: NTRP) today announced that a post-hoc analysis of data from its Phase 2 trial in patients with advanced Alzheimer's disease (AD) found evidence of improvement in cognition in patients receiving the 20μg bryostatin regimen who did not receive memantine, an approved AD treatment, as background therapy. The findings suggest this investigational drug could potentially help treat the progression of AD, rather than only its symptoms. The findings will be presented by Daniel Alkon, MD, President and Chief Scientific Officer of Neurotrope in
Dec 19, 2017 07:30 am ET
Neurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimer's Disease
NEW YORK, Dec. 19, 2017 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that it will present additional clinical findings from its Phase 2 bryostatin trial in patients with advanced AD in a keynote presentation at the Sachs' Neuroscience Innovation Forum on January 7 in San Francisco.
Dec 18, 2017 07:30 am ET
Neurotrope Appoints Charles S. Ryan as Chief Executive Officer
NEW YORK, Dec. 18, 2017 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced the appointment of Charles S. Ryan, JD, PhD as Chief Executive Officer and Director. The appointment follows the resignation of Susanne Wilke, PhD, as Chief Executive Officer and Director.
Aug 09, 2017 09:30 am ET
Neurotrope Provides Business Update and Reports Second Quarter 2017 Financial Results
NEW YORK, Aug. 9, 2017 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today provided a business update outlining recent clinical development progress and financial results for the quarter ended June 30, 2017.
Jul 19, 2017 12:16 pm ET
Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017
NEW YORK, July 19, 2017 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) today presented clinical results from its recently completed Phase 2 trial demonstrating that moderate-to-severe Alzheimer's disease (AD) patients treated with 20 µg bryostatin-1 showed preliminary evidence of sustained improvement in cognition compared to placebo. The data and comprehensive statistical analysis were presented in the Developing Topics: Clinical Trials oral session, "Effect of Bryostatin-1 on Cognition and Daily Living Tasks in Moderate to Severe Alzheimer's disease Preliminary Report of a Phase 2 Study"
Jul 17, 2017 01:10 pm ET
DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Neurotrope, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, July 17, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP) for possible violations of federal securities laws from January 7, 2016 through April 28, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Neurotrope shares during the Class Period should contact the firm by the July 17, 2017 lead plaintiff motion deadline....
Jul 14, 2017 04:55 pm ET
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Neurotrope, Inc. Shareholders and a Lead Plaintiff Deadline of July 17, 2017 (NTRP)
NEW YORK, July 14, 2017 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Neurotrope, Inc. (NASDAQ:NTRP) who purchased shares between January 7, 2016, and April 28, 2017. The action, which was filed in the U.S. District Court for the Southern District of New York, alleges that the Company violated federal securities laws....
Jul 14, 2017 04:06 pm ET
Rosen Law Firm Reminds Neurotrope, Inc. Investors of Important July 17 Deadline in Class Action - NTRP
NEW YORK, July 14, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Neurotrope, Inc. (NASDAQ: NTRP) from January 7, 2016 through April 28, 2017, both dates inclusive (the "Class Period") of important July 17, 2017 lead plaintiff deadline. The lawsuit seeks to recover damages for Neurotrope investors under the federal securities laws.
Jul 13, 2017 11:15 am ET
NTRP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Neurotrope, Inc. and a Lead Plaintiff Deadline of July 17, 2017
NEW YORK, July 13, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the U.S. District Court for the Southern District of New York on behalf of investors who purchased Neurotrope, Inc. ("Neurotrope") (NASDAQ:NTRP) securities between January 7, 2016, and April 28, 2017....
Jul 10, 2017 05:30 pm ET
7-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Neurotrope, Inc. and Encourages Investors with Losses to Contact the Firm
IRVINE, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP). Investors who purchased or otherwise acquired Neurotrope shares from January 7, 2016 through April 28, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the July 17, 2017 lead plaintiff motion deadline....
Jul 05, 2017 04:50 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Neurotrope, Inc. - NTRP
NEW YORK, July 5, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Neurotrope, Inc. securities (NASDAQ: NTRP) from January 7, 2016 through April 28, 2017, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for Neurotrope investors under the federal securities laws.
Jun 29, 2017 10:30 am ET
Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting
NEW YORK, June 29, 2017 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) today announced the acceptance of a late breaking oral presentation at the Alzheimer's Association International Conference 2017 (AAIC) being held in London from July 16 - 20, 2017.
Jun 23, 2017 05:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Neurotrope, Inc. of Class Action Lawsuit and Upcoming Deadline – NTRP
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Neurotrope, Inc. (“Neurotrope” or the “Company”) (NASDAQ:NTRP) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-04313, is on behalf of a class consisting of investors who purchased or otherwise acquired Neurotrope securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934....
Jun 23, 2017 05:27 pm ET
Rosen Law Firm Reminds Neurotrope, Inc. Investors of Important Deadline in Class Action – NTRP
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Neurotrope, Inc. (NASDAQ:NTRP) from January 7, 2016 through April 28, 2017, both dates inclusive (the “Class Period”) of important July 17, 2017 lead plaintiff deadline. The lawsuit seeks to recover damages for Neurotrope investors under the federal securities laws....
Jun 16, 2017 05:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Neurotrope, Inc. of Class Action Lawsuit and Upcoming Deadline - NTRP
NEW YORK, June 16, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Neurotrope, Inc. ("Neurotrope" or the "Company") (NASDAQ: NTRP) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-04313, is on behalf of a class consisting of investors who purchased or otherwise acquired Neurotrope securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.
Jun 01, 2017 05:29 pm ET
URGENT: Monteverde & Associates PC Invites Neurotrope, Inc. Shareholders with Losses To Contact The Firm Immediately - NTRP
NEW YORK, June 1, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York against Neurotrope, Inc. (NasdaqCM: NTRP)("Neurotrope" or the "Company") on behalf of purchasers of the Company's securities between January 7, 2016 and April 28, 2017, inclusive (the "Class Period").
May 30, 2017 07:29 pm ET
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Neurotrope, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, May 30, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP) concerning possible violations of federal securities laws between January 7, 2016 and April 28, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 17, 2017 lead plaintiff motion deadline....
May 30, 2017 02:38 pm ET
May 30, 2017 01:18 pm ET
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Neurotrope, Inc. and Encourages Investors with Losses to Contact the Firm
IRVINE, Calif., May 30, 2017 /PRNewswire/ -- Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Neurotrope, Inc. ("Neurotrope" or the "Company") (Nasdaq: NTRP). Investors who purchased or otherwise acquired shares between January 7, 2016 and April 28, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm in advance of the July 17, 2017 lead plaintiff motion deadline.
May 26, 2017 01:15 pm ET
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Neurotrope, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, May 26, 2017 /PRNewswire/ -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Neurotrope, Inc. ("Neurotrope" or the "Company") (Nasdaq: NTRP) concerning possible violations of federal securities laws between January 7, 2016 and April 28, 2017, inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 17, 2017 lead plaintiff motion deadline.
May 22, 2017 07:31 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Neurotrope, Inc. (NTRP)
NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP) in the United States District Court for the Southern District of New York on behalf of a class consisting of investors who purchased or otherwise acquired Neurotrope stock on the open market from January 7, 2016 through April 28, 2017, inclusive (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of the Securities Exchange Act of 1934....
May 22, 2017 06:36 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Neurotrope, Inc. To Contact The Firm
NEW YORK, May 22, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Neurotrope, Inc. ("Neurotrope" or the "Company") (NASDAQ:NTRP) of the July 17, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
May 19, 2017 06:55 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Neurotrope, Inc. To Contact The Firm
NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Neurotrope, Inc. (“Neurotrope” or the “Company”) (NASDAQ:NTRP) of the July 17, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
May 19, 2017 05:30 pm ET
Safirstein Metcalf LLP Announces That A Class Action Lawsuit Has Been Filed Against Neurotrope, Inc. - NTRP
NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Safirstein Metcalf LLP announces that a class action lawsuit has been filed against Neurotrope, Inc. (“Neurotrope” or the “Company”) (NASDAQ:NTRP) in the United States District Court for the Southern District of New York, and is filed on behalf of a class consisting of all persons or entities who acquired shares of Neurotrope between January 7, 2016, and April 28, 2017 (the "Class Period")....
May 19, 2017 04:47 pm ET
IMPORTANT Neurotrope, Inc. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Souther
NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Neurotrope, Inc. ("Neurotrope" or the "Company") (NASDAQ:NTRP) in the United States District Court for the Southern District of New York on behalf of shareholders who purchased Neurotrope securities between January 7, 2016, and April 28, 2017, both dates inclusive (the "Class Period")....
May 18, 2017 09:32 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Neurotrope, Inc. (NTRP) and Lead Plaintiff Deadline - July 17, 2017
NEW YORK, May 18, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Neurotrope, Inc. ("Neurotrope" or the "Company") (NASDAQ: NTRP) and certain of its officers, on behalf of shareholders who purchased Neurotrope securities between January 7, 2016, and April 28, 2017, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/ntrp.
May 17, 2017 05:15 pm ET
NTRP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Neurotrope, Inc.
NEW YORK, May 17, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:...
May 01, 2017 07:30 am ET
NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease
NEW YORK, May 1, 2017 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) today announced positive top-line results from its Phase 2 study (-202 Study) of Bryostatin-1 in patients with moderate to severe Alzheimer's disease (AD), a population not commonly targeted in AD clinical trials. Bryostatin-1, a Protein Kinase C epsilon activator that works through synaptic growth factors, as well as anti-amyloid and anti-tangle signaling pathways in the brain, has been shown, in non-clinical efficacy studies, to induce the growth of mature synapses in the brain and prevent neuronal death. Thus, Bryostati
Apr 28, 2017 08:30 am ET
Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017
NEW YORK, April 28, 2017 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, will issue a press release announcing results of top-line data from its 148 patient, Phase 2 clinical trial in moderate to severe Alzheimer's Disease, on Monday May 1, 2017, at 6:30 am, Eastern Time. A conference call will follow at 8:30 am Eastern Time on that date.
Mar 27, 2017 09:30 am ET
Neurotrope, Inc. Announces Approval for Listing on the NASDAQ Capital Market
NEW YORK, March 27, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced that it has received confirmation that its application to list the Company's common stock on the NASDAQ Capital Market has been approved by The NASDAQ Stock Market, a unit of the NASDAQ OMX Group. In honor of the listing, Neurotrope will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York City on March 31, 2017. The ceremony will begin at 9:15 a.m. ET
Mar 24, 2017 10:00 am ET
Neurotrope's President and Chief Scientific Officer to Present Keynote Address at Sachs Associates' 2nd Annual Neuroscience Biopartnering & Investment Forum
NEW YORK, March 24, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer' s disease, announced that Dr. Daniel Alkon, M.D., Neurotrope's President and Chief Scientific Officer, is scheduled to present at the Sachs Associates' 2nd Annual Neuroscience Biopartnering and Investment Forum, being held March 27, 2017 at the New York Academy of Sciences in New York City.
Mar 16, 2017 09:30 am ET
Neurotrope BioScience to Present at the Oppenheimer 27th Annual Healthcare Conference
NEW YORK, March 16, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer's disease, today announced that it is scheduled to present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 10:20 a.m. Eastern Time at the Westin New York Grand Central Hotel in New York, New York. Neurotrope's lead compound, bryostatin-1, has demonstrated, in extensive pre-clinical studies and early clinical observations, a unique potential for multi-modal effic
Feb 28, 2017 08:30 am ET
Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia
NEW YORK, Feb. 28, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, announced the conclusion of dosing and patient monitoring in its Phase 2 double blind, placebo controlled clinical trial of bryostatin-1 in the treatment of moderate to severe Alzheimer's dementia. Patients underwent a 12 week treatment with bryostatin-1, followed by a 30-day post-treatment evaluation. The study is designed to assess the therapeutic efficacy of bryostatin-1, a PKC epsilon
Feb 08, 2017 08:30 am ET
Neurotrope Bioscience to Present at the 19th Annual BIO CEO & Investor Conference 2017
NEW YORK, Feb. 8, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP / NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announces that Susanne Wilke PhD, Neurotrope's Chief Executive Officer, and Dr. Daniel Alkon, Neurotrope's President and Chief Scientific Officer, are scheduled to present at the 2017 BIO CEO & Investor Conference being held on February 13th-14th, 2017 at the Waldorf Astoria Hotel in New York City.
Jan 27, 2017 08:30 am ET
Neurotrope Bioscience to Present at the Noble Financial Capital Markets' 13th Annual Investor Conference
NEW YORK, Jan. 27, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, announced today that Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, is scheduled to present at the Noble Financial Capital Markets' 13th Annual NobleCON Conference, being held January 29-31, 2017 at the Boca Raton Resort in Boca Raton, Florida.
Jan 12, 2017 08:30 am ET
Neurotrope Announces Reverse Split of Common Stock in Preparation for NASDAQ Uplisting
NEW YORK, Jan. 12, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, announced today that its Board of Directors has approved a 1-for-32 reverse stock split of the Company's issued and outstanding common stock. The reverse stock split was effective prior to the stock market opening on January 12, 2017. With the successful implementation of the reverse stock split and provided that the Company's common stock meets the NASDAQ minimum bid price requirement, th
Jan 05, 2017 08:30 am ET
Neurotrope to Present at Two Upcoming Investor Conferences
NEW YORK, Jan. 5, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, announced today that Dr. Susanne Wilke, Ph.D., Neurotrope's Chief Executive Officer, will be presenting a corporate overview at two investor conferences:
Nov 23, 2016 09:31 am ET
Neurotrope Issues Statement On Eli Lilly's Solanezumab
NEW YORK, Nov. 23, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today issued a statement on Eli Lilly's experimental drug solanezumab. Lilly stated that, based upon results from its recent Phase 3 clinical trial, solanezumab failed to improve cognition of patients with mild Alzheimer's disease.
Nov 22, 2016 09:12 am ET
Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimer's Disease
NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCQB:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has initiated dosing in the final patient in its randomized, double-blinded, placebo-controlled, Phase 2 study in moderate to severe Alzheimer's disease patients. The primary endpoint of the trial is the Severe Impairment Battery (SIB) and the secondary endpoints are the Mini Mental State Exam (MMSE), Activity of Daily Living (ADL) and Neuropsychiatric Inventory scale (NPI). Top line results f
Nov 18, 2016 08:30 am ET
Neurotrope Announces Private Placement of $20 Million
NEW YORK, Nov. 18, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCQB:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it entered into a definitive securities purchase agreement with accredited investors to raise approximately $20.2 million in a private placement of common stock and warrants exercisable for common stock. In the private placement, the Company has agreed to sell shares of its common stock at a purchase price of $.20 per share and five-year warrants to purchase an equal number of the Company's shares
Sep 28, 2016 09:30 am ET
Dr. Daniel Alkon Appointed President of Neurotrope, Inc.
NEW YORK, Sept. 28, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCQB:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has appointed its Chief Scientific Officer, Dr. Daniel Alkon, to the additional role of President.
Sep 06, 2016 09:30 am ET
Susanne Wilke, PhD Appointed Chief Executive Officer of Neurotrope, Inc.
NEWARK, N.J., Sept. 6, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has appointed Dr. Susanne Wilke, PhD as Chief Executive Officer. Dr. Wilke brings significant leadership, sector and investing experience to Neurotrope based upon her work at leading biotechnology and pharmaceutical companies including Hoffman La Roche, Amgen, and Forest Labs. Dr. Wilke also served as a Kaufman Fellow at Schroder Ventures Life Sciences, a leading international Venture Cap
Aug 15, 2016 09:30 am ET
Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead Drug Candidate, Bryostatin-1, for the Treatment of Advanced Alzheimer's Dise
NEW YORK, Aug. 15, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCBB:NTRP) today announced that its wholly owned subsidiary, Neurotrope BioScience, Inc., has submitted to the Food and Drug Administration (FDA) an amended protocol for its Phase 2 clinical trial of lead candidate bryostatin-1 for the treatment of advanced Alzheimer's disease. As planned in the original protocol, the primary efficacy outcome will occur at Week 13, and does not change with this amendment. The primary efficacy endpoint is based on the Severe Impairment Battery scale, a well-validated assessment used extensively in sev
Aug 05, 2016 09:30 am ET
Neurotrope Announces Changes to the Board of Directors and Management
NEWARK, N.J., Aug. 5, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCBB: NTRP) (the "Company"), focused on developing drugs to treat neurological diseases including Alzheimer's disease, today announced it has reached a settlement agreement with Iroquois Master Fund Ltd. and certain of its affiliates (collectively "Iroquois"), with regard to a proposed consent solicitation by Iroquois.
Jun 23, 2016 09:30 am ET
Neurotrope announces that a new study published in the Journal of Biological Chemistry shows that Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Ancho
NEWARK, N.J., June 23, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) today announced that a study published in the Journal of Biological Chemistry shows that its lead Alzheimer's drug, Bryostatin, licensed from the Blanchette Rockefeller Neurosciences Institute (BRNI), increases the levels of the synaptic scaffolding protein PSD-95, and induces the movement of phosphorylated PSD-95 to the neuronal membranes. The study, conducted within the BRNI basic research programs, showed that Bryostatin induced activation of PKC epsilon increased synaptic number, pre-synaptic vesicle density, and
Jun 21, 2016 09:30 am ET
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
NEWARK, N.J., June 21, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP): today announced that Paula T. Trzepacz, M.D., has joined Neurotrope BioScience, Inc., the Company's wholly owned operating subsidiary, as its Executive Vice President and Chief Medical Officer.
Jun 13, 2016 09:30 am ET
Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease
NEWARK, N.J., June 13, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP): Dr. Daniel Alkon, Chief Scientific Officer of Neurotrope, discussed "Modulation of PKC Epsilon as a Therapeutic Strategy" as a potential treatment for both Fragile X mental retardation and Alzheimer's disease at the Autism-Related Disorders Gordon Conference.
May 19, 2016 09:30 am ET
Neurotrope Enters Into Research Collaboration With the International Rett Syndrome Foundation / Rettsyndrome.org
NEWARK, N.J., May 18, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer's disease (AD), is pleased to announce that it has entered into a research collaboration with the International Rett Syndrome Foundation, DBA: Rettsyndrome.org, to explore the potential of Bryostatin for the treatment of Rett syndrome.
Mar 08, 2016 08:30 am ET
Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model
NEWARK, N.J., March 08, 2016 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) today announced that its lead Alzheimer's drug Bryostatin improved disease symptoms and restored normal synaptic networks in a young transgenic animal model of Fragile X Syndrome (FXS), a common genetic cause of mental retardation and autism. The study led by scientists at the Blanchette Rockefeller Neuroscience Institute (BRNI) demonstrated that chronic treatment with bryostatin-1 rescues young fragile X mice (corresponding to 15 – 16 year old children) from the disorder phenotypes, including reversal of most FXS a
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.